Search for:

Search Medicine or Company Name Search Full Document

Advanced Search

BOOTS COMPANY PLC

1 Thane Road West, Beeston, Nottingham, NG2 3AA

Telephone: +44 (0)1159 595 306
Fax: +44 (0)1159 592 565

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?

Summary of Product Characteristics last updated on the eMC: 08/12/2011

SPC	Boots Sore Throat Relief Dual Action Lozenges Blackcurrant Flavour

Table of Contents

1. NAME OF THE MEDICINAL PRODUCT
2. QUALITATIVE AND QUANTITATIVE COMPOSITION
3. PHARMACEUTICAL FORM
4. CLINICAL PARTICULARS
4.1 Therapeutic indications
4.2 Posology and method of administration
4.3 Contraindications
4.4 Special warnings and precautions for use
4.5 Interaction with other medicinal products and other forms of interaction
4.6 Pregnancy and lactation
4.7 Effects on ability to drive and use machines
4.8 Undesirable effects
4.9 Overdose
5. PHARMACOLOGICAL PROPERTIES
5.1 Pharmacodynamic properties
5.2 Pharmacokinetic properties
5.3 Preclinical safety data
6. PHARMACEUTICAL PARTICULARS
6.1 List of excipients
6.2 Incompatibilities
6.3 Shelf life
6.4 Special precautions for storage
6.5 Nature and contents of container
6.6 Special precautions for disposal and other handling
7. MARKETING AUTHORISATION HOLDER
8. MARKETING AUTHORISATION NUMBER(S)
9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
10. DATE OF REVISION OF THE TEXT

Go to top of the page

1. NAME OF THE MEDICINAL PRODUCT

Boots Sore Throat Relief Dual Action Lozenges Blackcurrant Flavour

Go to top of the page

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Hexylresorcinol B.P. 2.4mg per lozenge

For excipients see section 6.1.

Go to top of the page

3. PHARMACEUTICAL FORM

Lozenge.

Go to top of the page

4. CLINICAL PARTICULARS

Go to top of the page

4.1 Therapeutic indications

As an antiseptic and local anaesthetic for the relief of sore throat and its associated pain.

Go to top of the page

4.2 Posology and method of administration

Adults, the Elderly, and Children aged 6 years and over :- One lozenge dissolved slowly in the mouth every three hours or as required. Do not take more than 12 lozenges in 24 hours.

Not to be given to children under 6 years.

Go to top of the page

4.3 Contraindications

Hypersensitivity to any of the ingredients.

Go to top of the page

4.4 Special warnings and precautions for use

Keep out of reach & sight of children. If symptoms persist consult your doctor. Not to be given to children under 6 years.

Contains a total of 2.4g of sucrose and liquid glucose solids per lozenge. Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine.

Go to top of the page

4.5 Interaction with other medicinal products and other forms of interaction

None known.

Go to top of the page

4.6 Pregnancy and lactation

The product is not contraindicated during pregnancy and lactation. However, as with all medicines during this period, caution should be exercised.

Go to top of the page

4.7 Effects on ability to drive and use machines

None known.

Go to top of the page

4.8 Undesirable effects

Reports of hypersensitivity reaction, including rash, urticaria and angioedema, are extremely rare. There have been very rare reports of tongue soreness.

Go to top of the page

4.9 Overdose

Hexylresorcinol overdosage may cause minor gastrointestinal irritation.

Treatment would be withdrawal of the product and symptomatic measures as appropriate.

Go to top of the page

5. PHARMACOLOGICAL PROPERTIES

Go to top of the page

5.1 Pharmacodynamic properties

Hexylresorcinol is a local anaesthetic for topical use on the mucous membranes of the mouth and throat. Mild antiseptic activity has also been demonstrated.

The product base has a demulcent action.

Go to top of the page

5.2 Pharmacokinetic properties

Pharmacokinetic considerations do not arise since the pharmacological action is local to the oro-pharangeal cavity.

Go to top of the page

5.3 Preclinical safety data

There is no preclinical data available specific to the product.

Go to top of the page

6. PHARMACEUTICAL PARTICULARS

Go to top of the page

6.1 List of excipients

Sucrose